Welcome to our dedicated page for AVAI BIO news (Ticker: AVAI), a resource for investors and traders seeking the latest updates and insights on AVAI BIO stock.
Avaí Bio, Inc. develops cell-based therapies centered on genetically modified cell lines, protective encapsulation technologies and joint venture or licensing structures. The company, formerly Avant Technologies Inc., uses the AVAI ticker and has described a biotechnology focus spanning diabetes, age-related disorders and anti-aging applications.
Recurring developments include the Insulinova diabetes program, which pairs insulin-producing or regulating cells with encapsulation technology, and the Klothonova α-Klotho program, which uses encapsulated cells designed to produce the longevity protein α-Klotho. Company updates also cover GMP manufacturing steps such as master cell bank production, research presentations, partner collaborations and the completed corporate name change to Avaí Bio.
Avant Technologies (OTCQB: AVAI) announced plans to establish a new company focused on diabetes treatment expansion. This development follows their successful joint venture with Ainnova Tech through Ai-nova Acquisition Corp (AAC), which utilizes the Vision AI platform for detecting diabetic retinopathy and other diseases.
The company's Vision AI technology can identify early markers of various conditions, including diabetic retinopathy, which affects over 30% of diabetes patients. With over 500 million people globally living with diabetes, Avant aims to expand from diagnosis to treatment through potential joint ventures, partnerships, or acquisitions.
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are exploring the integration of early dementia detection into Ainnova's Vision AI platform. The companies are considering either licensing or acquiring a patented technology that uses AI algorithms and hardware for dementia detection through a 5-minute blood test.
The Vision AI platform currently employs 4 integrated algorithms to assess risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data. The system utilizes an automated, low-cost retinal imaging device for comprehensive preventive risk screening.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech announced that Ainnova will sponsor and participate in the 2025 Healthcare Innovation Summit in Mexico City. Ainnova's CEO, Vinicio Vargas, will be a featured speaker presenting on "Preventative Healthcare with Artificial Intelligence: Breaking the Status Quo."
The companies have formed Ai-nova Acquisition Corp. (AAC), which holds global licensing rights for Ainnova's technology portfolio, including its Vision AI platform and retinal cameras. The Healthcare Innovation Summit Series is a global event bringing together key healthcare stakeholders to discuss healthcare transformation, focusing on system optimization, digital transformation, diagnostic technology, and infrastructure.
Avant Technologies (OTCQB: AVAI) and Ainnova Tech have entered acquisition negotiations to strengthen their position in the AI-driven healthcare industry. The companies, which formed Ai-nova Acquisition Corp (AAC) six months ago, are looking to consolidate before their FDA pre-submission meeting in July 2025 regarding clinical trials for the Vision AI platform in diabetic retinopathy detection.
AAC currently holds worldwide licensing rights for Ainnova's technology portfolio, which includes the Vision AI platform and retinal cameras. The proposed merger aims to streamline the advancement of their technology to market and enhance resource utilization. The companies believe consolidating operations will facilitate their FDA interactions and accelerate their entry into the U.S. market.
Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have initiated the design of their clinical trial protocol for the Vision AI platform, aimed at early detection of diabetic retinopathy. The company has hired an ophthalmologist to assist in drafting the protocol requirements for their CRO, Fortrea. The pre-submission meeting with the FDA is expected in mid-May 2025.
Ai-nova Acquisition Corp. (AAC), formed through the Avant-Ainnova partnership, holds global licensing rights for Ainnova's technology portfolio. The FDA pre-submission program will help determine the regulatory pathway, including patient and clinic requirements for clinical data generation, and help Avant establish a precise budget for the FDA process.